Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 3, 2010, Pages 1606-1608

  Miyake, Taichiro ^a   Sawada, Osamu ^a   Kakinoki, Masashi ^a   Sawada, Tomoko ^a   Kawamura, Hajime ^a   Ogasawara, Kazumasa ^a   Ohji, Masahito ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; LIMIT OF DETECTION; MACACA; MALE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG ANTAGONISM; HALF LIFE TIME; IMMUNOASSAY; INJECTION; METABOLISM; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; HALF-LIFE; IMMUNOASSAY; INJECTIONS; MACACA FASCICULARIS; MALE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77949887728     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4140     Document Type: Article

References (12)

1. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Vemlatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled openlabel clinical study. Ophthalmology. 2005;112:1035-1047.
2. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled openlabel clinical study. Ophthalmology. 2006;113:2002-2011.
3. Avery RL, Pearlman J, Pieramici D, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695-1705.
4. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-278.
5. Sawada O, Kawamura H, Kakinoki M, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007;125:1363-1366.
6. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855-859.
7. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-α in patients with choroidal neovascularization. Ophthalmology. 2008;115:1750-1755.
8. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508-512.
9. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
10. Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2005;243:3-8.
11. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009;50:1025-1032.
12. Sawada O, Kawamura H, Kakinoki M, Ohji M. Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246:1379-1381.